• Antibodies to HHV-6 during acute COVID-19 may help predict development of Long COVID

    Autoantibodies directed against neural targets have most predictive power.

  • iciHHV-6B linked to systemic lupus erythematosus (SLE) in Japanese and European populations

    iciHHV-6B, when integrated into chromosome 22q, was strongly associated with SLE and with SLE severity.

  • HHV-6 linked to miscarriage through Mendelian randomization studies

    The findings are consistent with previous studies directly linking HHV-6 endometrial infection to miscarriage.

  • Finnish investigators find unexpected evidence of HHV-6B integration into mitochondrial DNA

    Could HHV-6B infection exacerbate mitochondrial disease?

Newsletter | About Us | Contact Us | Donate | Repository

HHV-6 Foundation | HHV-6 Disease Information for Patients, Clinicians, and Researchers | Apply for a Grant Navigation
  • Home
  • About
    • Scientific Advisory Board
    • Staff
    • Contact Us
    • Donate
  • Patients
    • What Is HHV-6?
    • HHV-6A/B Testing
  • Research
    • Grants
    • Repository
      • Cart
      • Checkout
    • HHV-6A/B Testing
    • List of Genes & Proteins
    • Lab Protocols
    • Pictorial Atlas of HHV-6
    • HHV-6 Antivirals
    • Researcher FAQ
    • Newsletter
  • Home
  • About
    • Scientific Advisory Board
    • Staff
    • Contact Us
    • Donate
  • Patients
    • What Is HHV-6?
    • HHV-6A/B Testing
  • Research
    • Grants
    • Repository
      • Cart
      • Checkout
    • HHV-6A/B Testing
    • List of Genes & Proteins
    • Lab Protocols
    • Pictorial Atlas of HHV-6
    • HHV-6 Antivirals
    • Researcher FAQ
    • Newsletter

Latest Treatments – Antiviral Articles

View Post

A retrospective study of haploidentical alloHCT patients found no outcome differences between treated patients with high viral loads (log10 4.65) and untreated patients with lower viral loads (log10 3.84)

In All, Transplant Complications, Treatments - Antiviral by Kristin LoomisFebruary 5, 2025

Controlled studies are needed to determine the benefit of antiviral therapy in patients with high viral >10,000 copies/ mL.

View Post

After screening 100,000 compounds, Merck identified a potent broad-spectrum herpesvirus antiviral

In All, Treatments - Antiviral by Kristin LoomisSeptember 16, 2024

The new small molecule non-nucleoside inhibitor was effective in both in vitro and in vivo studies although no testing against HHV-6 was reported.

View Post

Why does substituting CMV-specific letermovir for broad-spectrum anti-viral prophylaxis reduce the rate of HHV-6B encephalitis?

In All, Transplant Complications, Treatments - Antiviral by Kristin LoomisJuly 29, 2024

Japanese study replicates the paradoxical results of a prior US study, but fails to explain the paradox.

View Post

Metformin reduces HHV-6A replication in T cells by activating AMPK

In All, Treatments - Antiviral by Kristin LoomisJune 25, 2024

Conversely, HHV-6A infection increases viral replication by inhibiting AMPK and enhancing mTOR signaling and glycolysis.

View Post

Adding antithymocyte globulin to post transplant cyclophosphamide prophylaxis does not increase risk of HHV-6 reactivation after haploidentical hematopoietic cell transplantation

In All, Transplant Complications, Treatments - Antiviral, Treatments - Immune Stimulant by Kristin LoomisMarch 4, 2024

The main risk factor for HHV-6 reactivation was low absolute lymphocyte count.

View Post

MS drug teriflunomide dramatically reduces antibody titers to EBV and HHV-6

In All, CNS Disease, Multiple Sclerosis, Treatments - Antiviral by Kristin LoomisMarch 4, 2024

Study results are consistent with a pathogenetic role for viruses in relapsing-remitting MS.

View Post

Strong Evidence Linking HHV-6B To Pneumonia in Transplant Patients

In All, Transplant Complications, Treatments - Antiviral by Kristin LoomisFebruary 3, 2024

Levels of mRNA transcripts indicating active infection strengthen case for pathogenic role.

View Post

Substituting letermovir for broad-spectrum ganciclovir for CMV prophylaxis did not increase HHV-6 disease in allogenic transplant patients

In All, Transplant Complications, Treatments - Antiviral by Kristin LoomisFebruary 3, 2024

Investigators were surprised that the use of the less toxic CMV specific antiviral did not result in a significant increase in HHV-6-related disease.

View Post

Small study finds relatively high foscarnet concentrations in CSF in HHV-6 encephalitis

In All, Antiviral, Encephalitis & Encephalopathy, Transplant Complications, Treatments - Antiviral by Kristin LoomisJuly 3, 2023

CSF foscarnet concentrati.ons were very near IC50 and were followed by sharp reductions in viral load.

View Post

Artesunate compares favorably to herpesvirus antivirals in suppressing HHV-6 and HHV-7

In All, Treatments - Alternative, Treatments - Antiviral by Kristin LoomisJanuary 9, 2023

Non-randomized study finds somewhat more potent reduction of virus in leucocytes over several months of treatment.

View Post

Failure to detect iciHHV-6 leads to overtreatment in hematopoietic cell transplant recipients

In All, Transplant Complications, Treatments - Antiviral by Kristin LoomisJanuary 3, 2022

Mistaking iciHHV-6 for a marked reactivation of naturally-acquired infection can lead to unnecessary diagnostic procedures and treatments, with adverse effects.

View Post

Foscarnet prophylaxis improved engraftment and survival in cord blood transplant patients

In All, Transplant Complications, Treatments - Antiviral by Kristin LoomisApril 22, 2021

Six-month overall survival was 96% in the treated group compared to 72% in the untreated group.

View Post

Oral brincidofovir prophylaxis for CMV decreased incidence of HHV-6B viremia

In All, Transplant Complications, Treatments - Antiviral by Kristin LoomisMay 31, 2020

Allogenic transplant patients who received prophylactic oral brincidofovir as part of a CMV trial had a reduced HHV-6B reactivation and lower viral loads.

View Post

Mori lab identifies a vaccine and immunotherapy target for HHV6-B

In All, Latest Scientific News, Treatments - Antiviral by Kristin LoomisApril 2, 2019

Rational vaccine design requires understanding details of protective immunity against each virus. Yasuko Mori and associates from Japan have now identified CD4+ and H-2Kd restricted CD8+ T-cell epitopes essential for HHV-6B viral entry, opening new possibilities for vaccines and immunotherapy.

View Post

Breakthrough on therapeutic HHV-6B neutralizing antibodies

In All, Immunity & Immunotherapy, Latest Scientific News, Treatments - Antiviral by Kristin LoomisApril 2, 2019

Yasuko Mori and colleagues were successful in humanizing two neutralizing monoclonal antibodies to HHV-6B. The chimeric antibodies performed well enough to show promise for therapeutic use.

  • Page 1 of 2
  • 1
  • 2
  • →

Clinical News

  • Alzheimer’s Disease
  • Animal Models
  • Autoimmune Disease
  • Cancer
  • iciHHV-6
  • CNS Disease
  • COVID-19 / HHV-6 Reactivation
  • Drug Hypersensitivity
  • Encephalitis & Encephalopathy
  • Endocrine Conditions
  • Epilepsy and Seizures
  • Gastrointestinal
  • Genes
  • Heart Disease
  • Hematological Disorders
  • HIV/AIDS Progression
  • Immunity & Immunotherapy
  • Infertility & Miscarriage
  • Kidney Disease
  • Liver Disease
  • Lung Disease
  • Lymphadenopathy & Fever
  • ME/CFS
  • Multiple Sclerosis
  • Rash & Roseola
  • Transplant Complications
  • Treatments – Adoptive T cell
  • Treatments – Alternative
  • Treatments – Antiviral
  • Treatments – Immune Stimulant

About HHV-6

  • What Is HHV-6?
  • What is Inherited Chromosomally Integrated HHV-6
  • HHV-6 Repository of Reagents
  • HHV-6A/B Testing
  • HHV-6 Treatment

SUBSCRIBE TO OUR NEWSLETTER

ABOUT THE HHV-6 FOUNDATION

The HHV-6 Foundation in a non-profit entity founded to encourage scientific exchange between investigators and to provide pilot grants for promising scientific and clinical research on the under- appreciated viruses HHV-6A and HHV-6B.

The Foundation sponsors international conferences and supports scientists and clinicians seeking to clarify the role of the two HHV-6 viruses in disease. Since HHV-6A and HHV-6B can smolder in the brain and other organs without circulating in the peripheral blood or plasma, identifying chronic infection is a challenge.

Read More

HHV-6 Foundation | 1482 East Valley Road, Suite 619 | Santa Barbara, CA, 93108 | Toll Free: (888) 530-6726


Copyright ©2004-2022 HHV-6 FOUNDATION


WEB DESIGN AND DEVELOPMENT BY INSTYLE TECHNOLOGIES
  • Home
  • About
  • Conditions
  • Clinicians
  • Testing
  • Research
  • Repository
  • Patients
  • Treatment
  • News & Blog
  • Donate
  • Contact Us
  • Cart
  • Checkout
  • Privacy Policy
  • Terms of Use